Treatment with TZDs has been demonstrated to improve insulin sensitivity in patients with T2DM after a 3-month treatment, and to reduce albuminuria, the last effect likely mediated by the concurrent increase in serum adiponectin concentration (Miyazaki et al., 2007). The gene discussed is INS; the disease is type 2 diabetes mellitus.